Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
Grifols announced the completion of the clinical portion of its SPARTA Phase 3 trial evaluating two dosage regimens of Prolastin®-C in patients with emphysema caused by alpha-1 antitrypsin deficiency (AATD). The trial enrolled 345 patients across 16 countries and utilized lung CT densitometry as the primary endpoint. The results are expected by the…